A phase II study of sunitinib malate (Sutent) and chemoembolization in patients with unresectable hepatocellular cancer.
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Sunitinib (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 18 Sep 2012 Planned end date changed from 1 Jan 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 30 May 2012 Planned End Date changed from 1 Mar 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov.